{"database":"biostudies-literature","file_versions":[],"scores":{"citationCount":0,"reanalysisCount":0,"viewCount":56,"searchCount":0},"additional":{"submitter":["Kim JE"],"funding":["National Research Foundation of Korea"],"pagination":["e166"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC7246187"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["35(20)"],"pubmed_abstract":["BACKGROUND:Post-transplant cancer (PTC) is a critical complication after kidney transplantation. However, whether successfully cured PTC affects the long-term graft outcome remains unclear. METHODS:We retrospectively reviewed 1,629 kidney transplant recipients from 1995 to 2017 after excluding patients with post-transplant hematologic or advanced non-curable cancers and who underwent allograft nephrectomy because of cancer. Cured PTCs were defined as cancers treated with curative methods and/or adjuvant therapy without recurrence during ≥ 2 years. Propensity score matching was performed to match cured PTC patients with cancer-naïve patients (i.e., non-PTC group). RESULTS:During the median period of 7 years (maximum, 23 years), 70 patients (4.3%) had cured PTCs. The PTC group showed significantly higher risks of death-censored graft failure (adjusted hazard ratio [HR], 2.56 [1.05-6.23]), class II donor-specific antibodies (adjusted HRs, 3.37 [1.30-8.71]), estimated glomerular filtration rate < 30 mL/min/1.73 m² (adjusted HR, 2.68 [1.43-5.02]) and random urine protein/creatinine ratio > 1 g (adjusted HR, 3.61 [1.92-6.79]) compared to non-PTC group. However, the risk of mortality was not different between the PTC and non-PTC groups. According to the cancer type, only urogenital cancer had a significant association with graft failure (adjusted HR, 4.26 [1.19-15.22]) and the gastrointestinal cancer showed elevated risk of T cell mediated rejection compared to non-PTC (adjusted HR, 20.44 [6.02-69.39]). CONCLUSION:Appropriate monitoring of graft function is necessary in patients with cured PTCs."],"journal":["Journal of Korean medical science"],"pubmed_title":["Risk of Graft Failure in Kidney Recipients with Cured Post-Transplant Cancer."],"pmcid":["PMC7246187"],"funding_grant_id":["2017R1D1A1B03031642"],"pubmed_authors":["Ha J","Kim JE","Lee H","Min SI","Han SS","Kim YS"],"view_count":["56"],"additional_accession":[]},"is_claimable":false,"name":"Risk of Graft Failure in Kidney Recipients with Cured Post-Transplant Cancer.","description":"BACKGROUND:Post-transplant cancer (PTC) is a critical complication after kidney transplantation. However, whether successfully cured PTC affects the long-term graft outcome remains unclear. METHODS:We retrospectively reviewed 1,629 kidney transplant recipients from 1995 to 2017 after excluding patients with post-transplant hematologic or advanced non-curable cancers and who underwent allograft nephrectomy because of cancer. Cured PTCs were defined as cancers treated with curative methods and/or adjuvant therapy without recurrence during ≥ 2 years. Propensity score matching was performed to match cured PTC patients with cancer-naïve patients (i.e., non-PTC group). RESULTS:During the median period of 7 years (maximum, 23 years), 70 patients (4.3%) had cured PTCs. The PTC group showed significantly higher risks of death-censored graft failure (adjusted hazard ratio [HR], 2.56 [1.05-6.23]), class II donor-specific antibodies (adjusted HRs, 3.37 [1.30-8.71]), estimated glomerular filtration rate < 30 mL/min/1.73 m² (adjusted HR, 2.68 [1.43-5.02]) and random urine protein/creatinine ratio > 1 g (adjusted HR, 3.61 [1.92-6.79]) compared to non-PTC group. However, the risk of mortality was not different between the PTC and non-PTC groups. According to the cancer type, only urogenital cancer had a significant association with graft failure (adjusted HR, 4.26 [1.19-15.22]) and the gastrointestinal cancer showed elevated risk of T cell mediated rejection compared to non-PTC (adjusted HR, 20.44 [6.02-69.39]). CONCLUSION:Appropriate monitoring of graft function is necessary in patients with cured PTCs.","dates":{"release":"2020-01-01T00:00:00Z","publication":"2020 May","modification":"2024-11-12T20:45:55.117Z","creation":"2020-06-04T07:09:54Z"},"accession":"S-EPMC7246187","cross_references":{"pubmed":["32449324"],"doi":["10.3346/jkms.2020.35.e166"]}}